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Abstract
Aims This study aimed to elucidate the molecular background of increased
Ca2+ sensitivity of force production in cardiomyocytes of end-stage human
heart failure.
Methods and results Ca2+-activated isometric force and the cross-bridge
speciﬁc rate of force redevelopment (ktr) were determined in Triton-skinned
myocytes from end-stage failing and non-failing donor hearts. Measurements
(control: pH 7.2, 0mM inorganic phosphate (Pi)) were performed under test
conditions that probed either the Ca2+-regulatory function of the thin ﬁla-
ments (pH 6.5), the kinetics of the actin-myosin cross-bridge cycle (10mM
Pi), or both (pH 6.5, 10mM Pi). The control maximal Ca
2+-activated force
(Fo) and ktrmax did not differ between failing and non-failing myocytes. At sub-
maximal [Ca2+], however, both force and ktr were higher in failing than in do-
nor myocytes. The difference in the Ca2+ sensitivities of force production was
preserved when the thin ﬁlament regulatory function was perturbed by acido-
sis (pH 6.5) but was abolished by cross-bridge modulation (i.e. by Pi) both at
pH 7.2 and at pH 6.5. Pi induced a larger reduction in force but a smaller in-
crease in ktr in the failing myocytes than in the non-failing myocytes at sub-
maximal [Ca2+].
Conclusion The enhanced Pi sensitivity of the actin-myosin interaction sug-
gests that the Pi release step of the actin-myosin cross-bridge cycle is modiﬁed
during end-stage human heart failure. This might be of functional importance
when Pi accumulates (e.g. during cardiac ischaemia). Moreover, this alteration
can inﬂuence cardiac energetics and the clinical efﬁcacy of sarcomere targeted
agents in human heart failure.
Keywords Human heart failure; Cardiomyocyte; Myoﬁlament; Actin-myosin
cross-bridge cycle
Introduction
Alterations in myocardial proteins (molecular remodelling) contribute to the
progressive diminution of cardiac performance during end-stage heart
failure.1,2 One of the factors involved in myocardial dysfunction is an increased
myoﬁbrillar Ca2+ sensitivity of force production, as a result of alterations in the
expression,3,4 and/or phosphorylation levels5–7 of contractile proteins.
Although interpretation of heart failure speciﬁc myoﬁbrillar protein changes
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is complicated by conﬂicting data of human hearts and of
animal models,8 it is generally accepted that down-
regulation of β-adrenergic signalling leads to hypophos-
phorylation of contractile proteins and consequently to
an increased Ca2+ sensitivity of force production during
end-stage human heart failure.9 Of note, phosphorylation
statuses of contractile proteins are the function of a
number of protein kinases and phosphatases, hence
allowing ﬁne tuning for contractile performance during
health and disease.8,10–12 In this regard, reduced levels
of phosphorylation for constituents of the thin ﬁlament
(e.g. troponin I) and of the thick ﬁlament (e.g. myosin
binding protein C, myosin light chain 2) have been con-
sistently documented for progressed stages of human
heart failure in association with ischaemic and/or di-
lated cardiomyopathy.7,13,14
The Ca2+ sensitivity of force production is a result of the
cooperative interplay between the thin and thick ﬁlaments
in striated muscles.15,16 Thus, it is controlled not only by
the Ca2+ regulation of the thin ﬁlaments17 but also by
the kinetic properties of the actin-myosin cross-bridge cy-
cle.18 The aim of this study was to reveal putative alter-
ations in the previous two processes in order to clarify
the mechanistic background of the increased Ca2+ sensi-
tivity of force production seen in association with end-
stage human heart failure. We hypothesize that changes
in the chemo-mechanical transduction of the actin-myosin
cross-bridge cycle is an integral element within the patho-
genesis of heart failure, where protein phosphorylation
plays a central mechanism.
To characterize the relationships between the Ca2+ sen-
sitivity and the kinetics of actin-myosin cross-bridges, the
[Ca2+] dependencies of isometric force production and
of ktr, i.e. the cross-bridge speciﬁc rate constant of tension
redevelopment after unloaded shortening and restretch,
were measured simultaneously in Triton-permeabilized
human left ventricular myocytes. Ca2+ regulation was
modulated by acidiﬁcation,17 while inorganic phosphate
(Pi) was added to probe the force-generating cross-bridge
transitions.19
Our results indicate that kinetic alterations of the cross-
bridge cycle have a direct impact on the Ca2+ sensitivity in
the human myocardium and may also affect the conver-
sion of chemical energy into force and shortening during
end-stage human heart failure.
Methods
Biopsies
Left ventricular biopsies were obtained during heart trans-
plantation surgery from three explanted end-stage failing
(New York Heart Association class IV) hearts (three males,
age range 45–65 years) and from three non-failing donor
hearts (two males, one female; age range 23–52years).
The heart failure resulted from ischaemic or dilated car-
diomyopathy. The cardiac tissue was transported in
cardioplegic solution, and upon arrival in the laboratory,
the tissue was stored in liquid nitrogen. Phosphorylation
levels of myoﬁbrillar proteins of failing and non-failing
myocardial tissue samples are given elsewhere.7 The in-
vestigation conforms with the principles outlined in the
Declaration of Helsinki.20 All samples were obtained after
informed consent had been received andwith the approval
of the local ethical committees, and the procedures
followed were in accordance with institutional guidelines.
Myocyte isolation
Cardiomyocytes (8–9 per biopsy, 52 in total) were isolated
mechanically and mounted in the experimental set-up as
described previously.21 0.5% Triton X-100 was used to re-
move all the membranous structures of the myocytes. This
allowed the study of myoﬁbrillar contractile properties in
the presence of a controlled intracellular environment
without the presence of disturbing factors in the intact
heart (i.e. hormonal factors, variable [Ca2+]) or in multi-
cellular preparations (myoﬁbrillar disarray, diffusion
limitations).
Experimental protocol
Isometric force measurements were performed at 15°C,
and sarcomere length was adjusted to 2.1μm in relaxing
solution. The compositions of the relaxing and activating
solutions used during force measurements were calcu-
lated as described by Fabiato (1981).22 The pCa levels of
the control (pH 7.2, 0mM Pi) relaxing and activating solu-
tions were 10 and 4.8, respectively. Solutions with other
free [Ca2+] were obtained by mixing of the activating
and relaxing solutions. After the ﬁrst control activation
(Fo) at saturating [Ca
2+] (pCa=4.8) (Figure 1A), the
resting sarcomere length was readjusted to 2.1μm if nec-
essary. The next four or ﬁve activations were carried out
under various experimental conditions, followed by a
bracketing control Fo determination. Measurements were
continued until Fo had decreased below 80% of the value
obtained at the beginning of the experiment. Force values
at submaximal [Ca2+] were expressed relative to the
nearest control Fo. To achieve maximal Ca
2+ activation
in the presence of 10mM Pi and/or at pH 6.5, appropriate
amounts of CaCl2 were added to the activating solutions
to cover a [Ca2+] range up to pCa 3.3.
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The rate of force redevelopment (ktr) was determined
by using release-restretch manoeuvers, as illustrated in
Figure 1B.23 At low [Ca2+] (P<25% of the control Fo),
the low signal-to-noise ratio prevented ktr determination.
Data analysis
Ca2+-force relations were ﬁtted to a modiﬁed Hill equa-
tion:
F ¼ Fo Ca2þ
 nHill
= Ca50nHill þ Ca2þ
 nHill 
where F is the steady-state force at a given [Ca2+], while
Fo, nHill, and Ca50 (or pCa50) denote the maximal Ca
2+-
activated force at saturating [Ca2+], the slope, and the
midpoint of the sigmoidal relationship, respectively.
All values in the text and ﬁgures are given as means
±S.E.M. Mean values were compared through unpaired
Student’s t-tests. Differences were considered signiﬁcant
when P<0.05.
Results
The isometric force (Fo) and the rate constant of tension
redevelopment (ktrmax) under control conditions (pH 7.2;
0mM Pi) for failing (38±4kNm
2 and 1.00±0.06 s1,
respectively) and the non-failing (36±3kNm2 and
0.93±0.02 s1) myocytes did not differ signiﬁcantly at
saturating [Ca2+]. In accordance with the ﬁndings in pre-
vious studies3,4,6 we observed an increased Ca2+ respon-
siveness of the contractile apparatus in end-stage failing
human myocardium (Figure 2A; ΔpCa50=0.15,
P<0.05). Our experiments also showed that not only
the isometric force but also ktr (Figure 2B) in failing
myocytes was markedly higher at submaximal [Ca2+]
(Δktr=0.16 s
1 at pCa 6.0) than in non-failing myocytes.
Modulation of the cross-bridge function by adding
10mM Pi decreased force at saturating [Ca
2+] to a similar
Figure 1 Panel A illustrates a force measurement on an isolated
myocardial cell. Rapid length changes at the peak of the force de-
velopment (at pCa 4.8; refer to also on the extended time scale in
B) and in relaxing solution (pCa 10) served the determination of
ktr and the passive force component (‘passive’). ktr was deﬁned
as the time constant of the exponential ﬁt (interrupted curve,
panel B) to the force recovery following unloaded shortening
(Δlength= 20% of the original segment length) and restretch
(‘release-restretch manoeuver’).
Figure 2 The Ca2+ dependence of isometric force production (A)
and the rate constant of tension redevelopment (ktr) (B) in the
absence or presence of 10mM inorganic phosphate (Pi) at pH
7.2 and pH 6.5. Closed symbols with continuous lines and open
symbols with dashed lines depict results for failing and non-fail-
ing myocytes, respectively. Corresponding force and ktr values
are indicated by identical symbols for all metabolic conditions.
The lines are the results of Hill ﬁts to the relative force values
in A. Error bars denote the S.E.M. when this is larger than the
size of the symbols, and asterisks (*) denote signiﬁcant differ-
ences between means of ktr values for failing and non-failing
myocytes.
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extent (to 41±2 and 40±1% respectively) in the failing
and non-failing myocytes. Pi induced a rightward shift in
the Ca2+-force relationship, which was, however, signiﬁ-
cantly larger for the failing myocytes than for the non-
failing myocytes. This completely eliminated the initial
difference in Ca2+ sensitivity between the failing and
non-failing myocytes (Figure 2A).
Modulation of the thin ﬁlament Ca2+-sensory function
by reducing the pH of the solutions from 7.2 to 6.5 caused
a similar decline in Fo (to 54±4and 59±3%, respectively)
in the failing and non-failing myocytes and also shifted the
Ca2+ sensitivity relations of the failing and non-failing
myocytes in an almost identical manner. However, also at
pH 6.5, the addition of 10mM Pi abolished the difference
in the Ca2+-force relations of the failing and non-failing
myocytes, (Figure 2A). An overview of the parameters de-
scribing the Ca2+-force relations is given in Table 1.
Pi caused a marked increase in ktrmax both in the failing
and in the non-failing myocytes (from 1.00±0.06 and
0.93±0.02 s1 to 1.97±0.09 and 2.22±0.11 s1, respec-
tively; P<0.05) (Figure 2B). However, there was one con-
spicuous difference: the Pi-induced increase in ktr for the
failing myocytes at submaximal [Ca2+] was signiﬁcantly
less than that for the non-failing myocytes. Acidosis in-
creased ktrmax by ~30% in both groups (to 1.28±0.08
and 1.32±0.12 s1 in the failing and non-failing
myocytes, respectively). Determination of ktr at pH 6.5
was feasible only between pCa 3.5 and pCa 4.71 and in
the absence of Pi. In these cases, no signiﬁcant difference
in ktr was observed between the failing and non-failing
myocytes.
Discussion
This study clearly shows the following: (1) the difference
in the Ca2+ sensitivities of force production between fail-
ing and non-failing myocardium is eliminated by 10mM
Pi. (2) Pi causes a smaller acceleration of the cross-bridge
kinetics in the failing than in the non-failing myocytes,
whereas modulation of the Ca2+-regulatory function of
the thin ﬁlament affects force generation similarly in fail-
ing and non-failing hearts.
In our previous studies, we have shown that the in-
creased Ca2+ responsiveness in failing human hearts most
likely results from deceased phosphorylation ofmyosin light
chain 2 and troponin I, in particular bisphosphorylation of
serines 23 and 24.23 However, we did not observe a differ-
ence inmyosin light chain 1 and troponinT phosphorylation
between donor and failing hearts.7,13
In this study, our primary aim was to explore the molec-
ular background of the altered cardiac pump function dur-
ing end-stage human heart failure. To obtain a more
detailed picture, the determination of Ca2+-force relation
was paralleled by ktr measurements in the absence or
presence of ischaemic metabolites.
Acidiﬁcation reduced pCa50 and the cooperativity
(nHill) of force production both in the failing and in the
non-failing myocytes, while the increase in ktrmax was
small. These ﬁndings are consistent with the notion that
the pH has a major impact on the Ca2+-binding function
of troponin C but has little direct effect on the transitions
between the weak and strong cross-bridge states.17 10mM
Pi reduced Fo more than acidosis, but it induced a smaller
rightward shift in the calcium-force relations and did not
change the Hill coefﬁcient either in the failing or in the
non-failing myocytes. These alterations, together with
the large increase seen in ktr, are in agreement with the
view that Pi, via reducing the overall free energy of
MgATP hydrolysis, affects the cross-bridges directly19,24,25
and has no direct effect on the Ca2+-binding function of tro-
ponin C.17 It is now generally accepted from animal studies
that Pi reverses the Pi-release step of the cross-bridge cycle
by mass action, thereby decreasing the proportion of cross-
bridges in the high-force conformation.19,24–26 Furthermore,
the Pi-induced changes in pCa50 are considered to be a conse-
quence of the altered distribution of actin-myosin states
within the cross-bridge cycle.17
An elevation in the rate of the cross-bridge transition
from the non-force-generating state to the force-
generating state (fapp) increases pCa50.
18 Under control
conditions, the higher ktr (fapp+gapp) values of the failing
myocardial cells are thus logically related with the ob-
served increase in pCa50. Reduction of the pH from 7.2
to 6.5 evoked comparable reductions in the Ca2+ sensitiv-
ities of force production and—with respect to ktr—it also
did not discriminate between the failing and the non-
Table 1 Parameters of Ca2+-force relations
Conditions Failing pCa50 Non-failing pCa50 Failing nHill Non-failing nHill Failing Fo Non-failing Fo
pH 7.2, 0mM Pi 5.97±0.04* 5.82± 0.01 2.49± 0.17* 2.99±0.13 1 1
pH 7.2, 10mM Pi 5.59±0.07
† 5.68± 0.02† 2.78± 0.44 3.10±0.23 0.41±0.02† 0.40± 0.01†
pH 6.5, 0mM Pi 4.94±0.08
*† 4.61± 0.09† 1.25± 0.27† 1.31±0.22† 0.54±0.04† 0.59± 0.03†
pH 6.5, 10mM Pi 4.59±0.19
† 4.47± 0.08† 1.10± 0.15† 1.00±0.07† 0.21±0.02† 0.22± 0.01†
*P< 0.05 vs non-failing myocytes.
†P< 0.05 vs control conditions (pH 7.2, 0mM Pi). Values were obtained on a total of 52 myocytes.
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failing myocytes. These observations suggest that the thin
ﬁlament regulation during human heart failure is not in-
trinsically altered despite a probable reduction in the level
of troponin I phosphorylation.5,7
In contrast, the Pi sensitivity of pCa50 and ktr differed
signiﬁcantly between the failing and the non-failing
myocytes. Pi decreased pCa50 more, whereas it increased
the Ca2+ sensitivity of ktr less in the failing myocytes than
in the non-failing myocytes. It is concluded, therefore,
that the molecular interplay between cross-bridge transi-
tions and the Ca2+ sensitivity of force production is char-
acteristically altered in the failing human heart. This
most likely involves the chemo-mechanical transduction
process per se through a reduction in the rate of the Pi-re-
lease step and/or enhancement of the reverse reaction.
The elimination of the higher Ca2+ sensitivity of force pro-
duction by 10mM Pi in the failing myocytes occurred both
at pH 7.2 and at pH 6.5, in perfect agreement with the no-
tion that the Pi effect is independent from that of
protons.24,27
Functional implications
The Fo and ktrmax values at saturating [Ca
2+] of failing
and non-failing human myocytes did not differ signiﬁ-
cantly from each other under any metabolic conditions
and thus corroborated previous ﬁndings of our group.27
During physiological cardiac activity, the thin ﬁlaments
are far from Ca2+ saturation. Differences in the mechani-
cal parameters of failing and non-failing hearts at inter-
mediate [Ca2+] therefore bear important functional
consequences for the cardiac performance. The increase
in the apparent Ca2+ sensitivity of force production might
be deleterious for the diastolic function, but it could po-
tentially compensate for the reduced amplitude of the
Ca2+ transient during systole. Here, we show that the dis-
turbance in cross-bridge cycling is coupled to an enhanced
Pi dependence of Ca
2+ sensitivity in failing myocardium.
Hence, Pi accumulation, e.g. during ischaemia, may elim-
inate the advantage of an increased Ca2+ reactivity.
Moreover, slowing of the Pi-release step might explain
the increased economy of contraction observed in failing
hearts.26 Nevertheless, it is to be acknowledged that
end-stage heart failure is a complex syndrome, where
in addition to alterations of sarcomeric proteins in
cardiomyocytes, pump function may also depend on
the largely unknown interplay of numerous cell types
in the myocardium.
Recent pharmacological research resulted in the devel-
opment of so-called direct myosin activator agents for the
management of systolic heart failure.28 These drugs bind
to the myosin catalytic domain and operate by an alloste-
ric mechanism through the modulation of Pi-dependent
myosin function. In animal models of heart failure, car-
diac myosin activation gave promising results, while in
humans, convincing results are still awaited.29 Our pres-
ent results imply that the eventual success of new sarco-
mere targeted agents will depend not only on their
pharmacokinetic binding characteristics to a well-deﬁned
target molecule but rather on their complex action on
the actin-myosin cross-bridge cycle during human heart
failure.
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